The abstract is read at the publisher; the summary is JClub's.
Dual LAG-3/PD-1 blockade with IBI110 plus sintilimab in advanced alveolar soft part sarcoma achieved an overall response rate of 51.8% (14/27).
- Why it matters: PD-1/PD-L1 inhibitors show limited responses in advanced ASPS, and LAG-3 coexpression with PD-1 on exhausted T cells suggests dual blockade could improve outcomes.
- What they did: In an open-label phase II single-center trial, 28 patients received intravenous IBI110 and sintilimab at 200 mg every 3 weeks, with RECIST v1.1 as the primary endpoint.
- The result: Responses were 60% in ICI-naïve patients and 25% in ICI-resistant patients, with median PFS/OS not reached overall; grade 3–4 treatment-related adverse events occurred in 32.1%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.